This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lebeau, A. Articles by Löhrs, U. Search for Related Content PubMed PubMed Citation Articles by Lebeau, A. Articles by Löhrs, U. Social Bookmarking                            What's this?

HER-2/neu Analysis in Archival Tissue Samples of Human Breast Cancer: Comparison of Immunohistochemistry and Fluorescence In Situ Hybridization

Pathologisches Institut and Klinik für Frauenheilkunde und Geburtshilfe Klinikum-GroBhadern, Ludwig-Maximilians-Universität, München, Germany.

Address reprint requests to Annette Lebeau, MD, Pathologisches Institut der Universität, Thalkirchner Str 36, 80337 München, Germany; email a.lebeau{at}lrz.uni-muenchen.de

PURPOSE: The objective of our study was to compare the methods used in the literature to analyze HER-2/neu status on archival breast cancer tissue. Therefore, a series of antibodies was evaluated to assess their immunohistochemical (IHC) sensitivity in correlation to gene amplification determined by fluorescence in situ hybridization (FISH).

MATERIALS AND METHODS: HER-2/neu overexpression was studied on paraffin sections of 85 invasive breast cancers using a panel of five monoclonal (9G6, 3B5, CB11, TAB250, GSF-HER2) and two polyclonal antibodies (A8010, A0485) in addition to the HercepTest (DAKO, Glostrup, Denmark). HER-2/neu gene amplification was determined by FISH using a dual-color probe (PathVysion; Vysis, Stuttgart-Fasanenhof, Germany).

RESULTS: HER-2/neu overexpression was demonstrated in 26% (9G6, TAB250, GSF-HER2), 27% (3B5, CB11), 33% (A8010) and 42% (A0485, HercepTest) of the tumors. FISH on paraffin sections identified gene amplification in 28% of the tumors. Strongly positive IHC results (3+) were always associated with gene amplification. Among the 16 tumors presented with weakly positive IHC results (2+) using the HercepTest, 12 (75%) lacked gene amplification.

CONCLUSION: The comparison of IHC and FISH demonstrated an excellent correlation of high-level HER-2/neu overexpression (3+) with gene amplification; ie, FISH does not provide further information in these tumors. However, weakly positive IHC results (2+) obtained with the HercepTest share only a minor association with gene amplification.

This study contains parts of the doctoral thesis of D.D.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J Zustin, K Boddin, M C Tsourlakis, E Burandt, M Mirlacher, F Jaenicke, J Izbicki, W Ruether, J M Rueger, C Bokemeyer, et al. HER-2/neu analysis in breast cancer bone metastases J. Clin. Pathol., June 1, 2009; 62(6): 542 - 546. [Abstract] [Full Text] [PDF]

				N. Harbeck, I. Nimmrich, A. Hartmann, J. S. Ross, T. Cufer, R. Grutzmann, G. Kristiansen, A. Paradiso, O. Hartmann, A. Margossian, et al. Multicenter Study Using Paraffin-Embedded Tumor Tissue Testing PITX2 DNA Methylation As a Marker for Outcome Prediction in Tamoxifen-Treated, Node-Negative Breast Cancer Patients J. Clin. Oncol., November 1, 2008; 26(31): 5036 - 5042. [Abstract] [Full Text] [PDF]

				R A Walker, J M S Bartlett, M Dowsett, I O Ellis, A M Hanby, B Jasani, K Miller, and S E Pinder HER2 testing in the UK: further update to recommendations J. Clin. Pathol., July 1, 2008; 61(7): 818 - 824. [Abstract] [Full Text] [PDF]

				C L Hyun, H E Lee, K S Kim, S-W Kim, J H Kim, G Choe, and S Y Park The effect of chromosome 17 polysomy on HER-2/neu status in breast cancer J. Clin. Pathol., March 1, 2008; 61(3): 317 - 321. [Abstract] [Full Text] [PDF]

				C. A. Hudis Trastuzumab -- Mechanism of Action and Use in Clinical Practice N. Engl. J. Med., July 5, 2007; 357(1): 39 - 51. [Full Text] [PDF]

				N. Dendukuri, K. Khetani, M. McIsaac, and J. Brophy Testing for HER2-positive breast cancer: a systematic review and cost-effectiveness analysis Can. Med. Assoc. J., May 8, 2007; 176(10): 1429 - 1434. [Abstract] [Full Text] [PDF]

				N. Yaal-Hahoshen, S. Shina, L. Leider-Trejo, I. Barnea, E. L. Shabtai, E. Azenshtein, I. Greenberg, I. Keydar, and A. Ben-Baruch The Chemokine CCL5 as a Potential Prognostic Factor Predicting Disease Progression in Stage II Breast Cancer Patients Clin. Cancer Res., August 1, 2006; 12(15): 4474 - 4480. [Abstract] [Full Text] [PDF]

				S. Rodenhuis, M. Bontenbal, Q. G. C. M. van Hoesel, W. M. Smit, M. A. Nooij, E. E. Voest, E. van der Wall, P. Hupperets, H. van Tinteren, J. L. Peterse, et al. Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer Ann. Onc., April 1, 2006; 17(4): 588 - 596. [Abstract] [Full Text] [PDF]

				E. Li-Ning-T, R. Ronchetti, C. Torres-Cabala, and M. J. Merino Role of Chromogenic in Situ Hybridization (CISHTM) in the Evaluation of HER2 Status in Breast Carcinoma: Comparison with Immunohistochemistry and Fish International Journal of Surgical Pathology, October 1, 2005; 13(4): 343 - 351. [Abstract] [PDF]

				R Ainsworth, J M S Bartlett, J J Going, E A Mallon, A Forsyth, J Richmond, W Angerson, A Watters, and B Dunne IHC for Her2 with CBE356 antibody is a more accurate predictor of Her2 gene amplification by FISH than HercepTestTM in breast carcinoma J. Clin. Pathol., October 1, 2005; 58(10): 1086 - 1090. [Abstract] [Full Text] [PDF]

				Y. Ma, L. Lespagnard, V. Durbecq, M. Paesmans, C. Desmedt, M. Gomez-Galdon, I. Veys, F. Cardoso, C. Sotiriou, A. Di Leo, et al. Polysomy 17 in HER-2/neu Status Elaboration in Breast Cancer: Effect on Daily Practice Clin. Cancer Res., June 15, 2005; 11(12): 4393 - 4399. [Abstract] [Full Text] [PDF]

				B. M. Slomovitz, R. R. Broaddus, T. W. Burke, N. Sneige, P. T. Soliman, W. Wu, C. C. Sun, M. F. Munsell, D. M. Gershenson, and K. H. Lu Her-2/neu Overexpression and Amplification in Uterine Papillary Serous Carcinoma J. Clin. Oncol., August 1, 2004; 22(15): 3126 - 3132. [Abstract] [Full Text] [PDF]

				L. Zhu, L. W. C. Chow, W. T. Y. Loo, X.-Y. Guan, and M. Toi Her2/neu Expression Predicts the Response to Antiaromatase Neoadjuvant Therapy in Primary Breast Cancer: Subgroup Analysis from Celecoxib Antiaromatase Neoadjuvant Trial Clin. Cancer Res., July 15, 2004; 10(14): 4639 - 4644. [Abstract] [Full Text] [PDF]

				J. Isola, M. Tanner, A. Forsyth, T. G. Cooke, A. D. Watters, and J. M. S. Bartlett Interlaboratory Comparison of HER-2 Oncogene Amplification as Detected by Chromogenic and Fluorescence in situ Hybridization Clin. Cancer Res., July 15, 2004; 10(14): 4793 - 4798. [Abstract] [Full Text] [PDF]

				C. T. Dang, A. J. Dannenberg, K. Subbaramaiah, M. N. Dickler, M. M. Moasser, A. D. Seidman, G. M. D'Andrea, M. Theodoulou, K. S. Panageas, L. Norton, et al. Phase II Study of Celecoxib and Trastuzumab in Metastatic Breast Cancer Patients Who Have Progressed after Prior Trastuzumab-Based Treatments Clin. Cancer Res., June 15, 2004; 10(12): 4062 - 4067. [Abstract] [Full Text] [PDF]

				H. Yaziji, L. C. Goldstein, T. S. Barry, R. Werling, H. Hwang, G. K. Ellis, J. R. Gralow, R. B. Livingston, and A. M. Gown HER-2 Testing in Breast Cancer Using Parallel Tissue-Based Methods JAMA, April 28, 2004; 291(16): 1972 - 1977. [Abstract] [Full Text] [PDF]

				E. B. Elkin, M. C. Weinstein, E. P. Winer, K. M. Kuntz, S. J. Schnitt, and J. C. Weeks HER-2 Testing and Trastuzumab Therapy for Metastatic Breast Cancer: A Cost-Effectiveness Analysis J. Clin. Oncol., March 1, 2004; 22(5): 854 - 863. [Abstract] [Full Text] [PDF]

				A. Handra-Luca, H. Bilal, J.-C. Bertrand, and P. Fouret Extra-Cellular Signal-Regulated ERK-1/ERK-2 Pathway Activation in Human Salivary Gland Mucoepidermoid Carcinoma: Association to Aggressive Tumor Behavior and Tumor Cell Proliferation Am. J. Pathol., September 1, 2003; 163(3): 957 - 967. [Abstract] [Full Text] [PDF]

				C. Pellegrini, M. Falleni, A. Marchetti, B. Cassani, M. Miozzo, F. Buttitta, M. Roncalli, G. Coggi, and S. Bosari HER-2/Neu Alterations in Non-Small Cell Lung Cancer: A Comprehensive Evaluation by Real Time Reverse Transcription-PCR, Fluorescence in Situ Hybridization, and Immunohistochemistry Clin. Cancer Res., September 1, 2003; 9(10): 3645 - 3652. [Abstract] [Full Text] [PDF]

				I. Zemzoum, R. E. Kates, J. S. Ross, P. Dettmar, M. Dutta, C. Henrichs, S. Yurdseven, H. Hofler, M. Kiechle, M. Schmitt, et al. Invasion Factors uPA/PAI-1 and HER2 Status Provide Independent and Complementary Information on Patient Outcome in Node-Negative Breast Cancer J. Clin. Oncol., March 15, 2003; 21(6): 1022 - 1028. [Abstract] [Full Text] [PDF]

				S. M. Ali, K. Leitzel, V. M. Chinchilli, L. Engle, L. Demers, H. A. Harvey, W. Carney, J. W. Allard, and A. Lipton Relationship of Serum HER-2/neu and Serum CA 15-3 in Patients with Metastatic Breast Cancer Clin. Chem., August 1, 2002; 48(8): 1314 - 1320. [Abstract] [Full Text] [PDF]

				S. Paik, J. Bryant, E. Tan-Chiu, E. Romond, W. Hiller, K. Park, A. Brown, G. Yothers, S. Anderson, R. Smith, et al. Real-World Performance of HER2 Testing--National Surgical Adjuvant Breast and Bowel Project Experience J Natl Cancer Inst, June 5, 2002; 94(11): 852 - 854. [Abstract] [Full Text] [PDF]

				C. Van Poznak, L. Tan, K. S. Panageas, C. D. Arroyo, C. Hudis, L. Norton, and A. D. Seidman Assessment of Molecular Markers of Clinical Sensitivity to Single-Agent Taxane Therapy for Metastatic Breast Cancer J. Clin. Oncol., May 1, 2002; 20(9): 2319 - 2326. [Abstract] [Full Text] [PDF]

				R. Tubbs, J. Pettay, M. Skacel, R. Powell, M. Stoler, P. Roche, and J. Hainfeld Gold-Facilitated in Situ Hybridization : A Bright-Field Autometallographic Alternative to Fluorescence in Situ Hybridization for Detection of HER-2/neu Gene Amplification Am. J. Pathol., May 1, 2002; 160(5): 1589 - 1595. [Abstract] [Full Text] [PDF]

				D. W. Nichols, D. J. Wolff, S. Self, J. S. Metcalf, D. Jacobs, R. Kneuper-Hall, and J. C. Cate IV A Testing Algorithm for Determination of HER2 Status in Patients with Breast Cancer Ann. Clin. Lab. Sci., January 1, 2002; 32(1): 3 - 11. [Abstract] [Full Text] [PDF]

				G. Konecny, M. Untch, J. Arboleda, C. Wilson, S. Kahlert, B. Boettcher, M. Felber, M. Beryt, S. Lude, H. Hepp, et al. HER-2/neu and Urokinase-Type Plasminogen Activator and Its Inhibitor in Breast Cancer Clin. Cancer Res., August 1, 2001; 7(8): 2448 - 2457. [Abstract] [Full Text] [PDF]

				E. A. Eisenhauer From the Molecule to the Clinic -- Inhibiting HER2 to Treat Breast Cancer N. Engl. J. Med., March 15, 2001; 344(11): 841 - 842. [Full Text] [PDF]